Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.07.095
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Establishing a Histology-Specific Biologically Effective Dose Threshold for Lung Stereotactic Ablative Radiotherapy (SABR): Is ≥100 Gy10 Enough?

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Stereotactic Ablative Radiotherapy Outcomes for Metastatic Adrenal Gland Tumors in Lung Cancer Based on Histology Subtype and Molecular Profile

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

MS20.02 the Future of Stereotactic Ablative Radiotherapy (SABR)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Stereotactic Body Radiotherapy for Prostate Cancer: Ready for Prime Time?

Journal of Radiation Oncology
OncologyRadiologyNuclear MedicineImaging
2012English

Imaging Follow-Up After Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors

Journal of Radiation Oncology
OncologyRadiologyNuclear MedicineImaging
2012English

Are We Ready for Electric Cars?

Journal of KONES
2019English

Utilization of Stereotactic Ablative Radiotherapy in the Management of Oligometastatic Disease

Current Oncology
Oncology
2014English

Primary Lung Sarcoma Treated With Stereotactic Ablative Radiotherapy: A Case Report

OncoTargets and Therapy
OncologyPharmacology
2017English

Explaining AI: Are We Ready for It?

KI - Künstliche Intelligenz
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy